Beta-Blockers in Glaucoma: Board Review
Learn how beta-blockers and timolol lower IOP, their major contraindications and the board-tested role of betaxolol.
Timolol belongs to which class of glaucoma medication?
Beta-Blockers in Glaucoma in 30 Seconds
Topical beta-blockers lower intraocular pressure by reducing aqueous humor production by the nonpigmented ciliary epithelium. Timolol is the prototype and is used as a second-line agent after prostaglandin analogs, especially when additional pressure lowering is needed.
Mechanism and IOP Lowering
Beta-adrenergic receptor blockade in the nonpigmented ciliary epithelium reduces aqueous humor production. Non-selective agents block both beta-1 and beta-2 receptors, while betaxolol is beta-1 selective. They lower IOP by about 20 to 25%, less than prostaglandin analogs, and do not increase aqueous outflow. Because aqueous production decreases physiologically at night, beta-blockers provide less additional nocturnal IOP reduction than during the day, which explains the preference for morning twice-daily dosing.
Agents in This Class
- Timolol 0.5% and 0.25%: prototype non-selective beta-blocker, twice daily or once daily as gel-forming solution (Timoptic-XE). Exam relevance: the reference second-line glaucoma agent.
- Betaxolol: beta-1 selective with relatively less bronchospasm risk but slightly less IOP lowering than timolol. Exam relevance: preferred consideration when pulmonary disease limits non-selective agents.
- Levobunolol: non-selective, dosed once or twice daily. Exam relevance: timolol-like alternative.
- Carteolol: non-selective with intrinsic sympathomimetic activity. Exam relevance: the ISA property distinguishes it pharmacologically.
Systemic Side Effects and Contraindications
- Bronchospasm: contraindicated in asthma and generally avoided in patients with significant COPD. Exam relevance: beta-2 blockade can precipitate bronchospasm in reactive airways.
- Bradycardia and heart block: systemic absorption may suppress cardiac conduction. Exam relevance: avoid in significant bradycardia, second or third degree heart block and decompensated heart failure.
- Masking hypoglycemia: blunts tachycardia from hypoglycemia. Exam relevance: use caution in insulin-dependent diabetics.
- CNS effects: depression, fatigue and sexual dysfunction reported. Exam relevance: topical therapy can cause systemic CNS effects.
- Betaxolol: beta-1 selectivity provides a relative pulmonary safety advantage. Exam relevance: still requires caution in pulmonary disease, not risk-free.
- Combined topical and systemic beta-blockers: may provide less additional IOP lowering than expected while increasing systemic adverse effects. Exam relevance: always ask about systemic beta-blocker use before prescribing.
4 Facts Exams Always Ask
- Timolol reduces aqueous production by non-selective beta-adrenergic blockade in the nonpigmented ciliary epithelium.
- Contraindicated in asthma and generally avoided in significant COPD. Also contraindicated in significant bradycardia, second or third degree heart block and decompensated heart failure.
- Betaxolol is beta-1 selective and has relatively less bronchospasm risk than non-selective agents, though it is not risk-free in pulmonary disease.
- Aqueous production decreases physiologically at night, so beta-blockers have less nocturnal IOP-lowering effect, explaining the preference for morning dosing.
The Classic Trap
Do not prescribe a non-selective beta-blocker to a patient with asthma, because beta-2 blockade can cause bronchospasm. Do not forget that topical eye drops undergo clinically meaningful systemic absorption and may cause bradycardia or heart block, especially in older patients or those already on oral beta-blockers or calcium channel blockers. Nasolacrimal occlusion or eyelid closure for at least 2 minutes reduces systemic absorption.
Clinical Pearl
Topical beta-blockers enter systemic circulation through the nasolacrimal duct. Nasolacrimal occlusion or eyelid closure for 2 to 5 minutes after instillation substantially reduces systemic absorption. Ask specifically about asthma, COPD, cardiac disease and systemic beta-blocker use before prescribing. Combining a topical and oral beta-blocker may reduce the expected additional IOP benefit while compounding systemic effects.
Checkpoint 1
Which topical beta-blocker is relatively beta-1 selective compared with timolol?
Checkpoint 2
Timolol is contraindicated in a patient with which comorbidity due to systemic absorption via the nasolacrimal duct?
A 71-year-old patient with primary open-angle glaucoma needs additional IOP lowering despite a prostaglandin analog. He has COPD controlled with inhalers and no cardiac history. The clinician is considering timolol or betaxolol. Which agent is the safer beta-blocker choice, and what risk still requires counseling?
A 71-year-old patient with POAG and COPD needs additional IOP lowering beyond a prostaglandin analog. If a topical beta-blocker is chosen, which agent is the safer option and why?
Sources & Publisher Info
Last clinically reviewed: August 9, 2026
References
- American Academy of Ophthalmology. Basic and Clinical Science Course, Section 10: Glaucoma.
- American Academy of Ophthalmology. EyeWiki: Glaucoma Medical Therapy.
- American Academy of Ophthalmology. EyeWiki: Topical Glaucoma Medications.
More Pharmacology topics
Ready for the real thing?
Practice thousands of eye-care questions free on OcuQuiz. Earn points, build streaks and battle colleagues.
Practice Pharmacology →